Boye Shannon E
Departments of Ophthalmology and Molecular Genetics and Microbiology, University of Florida, 1600 SW Archer Rd, Academic Research Building Rm R2-236, 32621, Gainesville, FL, USA.
Adv Exp Med Biol. 2016;854:253-8. doi: 10.1007/978-3-319-17121-0_34.
GUCY2D encodes retinal guanylate cylase-1 (retGC1), a protein that plays a pivotal role in the recovery phase of phototransduction. Mutations in GUCY2D are associated with a leading cause of recessive Leber congenital amaurosis (LCA1). Patients present within the first year of life with aberrant or unrecordable electroretinogram (ERG), nystagmus and a relatively normal fundus. Aside from abnormalities in the outer segments of foveal cones and, in some patients, foveal cone loss, LCA1 patients retain normal retinal laminar architecture suggesting they may be good candidates for gene replacement therapy. Several animal models of LCA1, both naturally occurring and engineered, have been characterized and provide valuable tools for translational studies. This mini-review will summarize the phenotypes of these models and describe how each has been instrumental in proof of concept studies to develop a gene replacement therapy for GUCY2D-LCA1.
GUCY2D基因编码视网膜鸟苷酸环化酶-1(retGC1),该蛋白在光转导的恢复阶段起关键作用。GUCY2D基因突变与隐性莱伯先天性黑蒙(LCA1)的主要病因相关。患者在出生后第一年内出现异常或无法记录的视网膜电图(ERG)、眼球震颤和相对正常的眼底。除了中央凹视锥细胞外段异常以及部分患者中央凹视锥细胞缺失外,LCA1患者的视网膜各层结构保持正常,这表明他们可能是基因替代疗法的良好候选者。已经对几种自然发生和人工构建的LCA1动物模型进行了表征,这些模型为转化研究提供了有价值的工具。本综述将总结这些模型的表型,并描述每种模型如何在概念验证研究中发挥作用,以开发针对GUCY2D-LCA1的基因替代疗法。